Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track RNAC with free AI briefings, catalyst countdowns, and dilution alerts.

RNAC · Cartesian Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$123M Cash on Hand
15.1mo Cash Runway
13.6% Short Interest
$33.67 Analyst Target (6)
Follow RNAC by email Get an email when RNAC reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about RNAC, unsubscribe in one click. Privacy

📣 What RNAC Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Decartes-08 Myasthaenia Gravis Phase 3 · NCT06799247 Active not recruiting
Autologous Anti-BCMA-CAR-mRNA-transfected CD8+… Myeloma Multiple Phase 2 · NCT04816526 Terminated
Autologous Anti-BCMA CD8+ CAR T-cells… Multiple Myeloma Phase 2 · NCT04436029 Completed
Descartes 30 Acute Respiratory Distress Syndrome Phase 1 · NCT04524962 Terminated
Descartes-15 Refractory Multiple Myeloma Phase 1 · NCT06304636 Terminated
Descartes-25 Multiple Myeloma Phase 1 · NCT05113342 Terminated
Fludarabine Multiple Myeloma Phase 1 · NCT03994705 Terminated

Also used in these trials (approved or third-party drugs, not RNAC's own candidates): Cyclophosphamide.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

RNAC holds $123M in cash and short-term investments (as of Sep 30, 2026) and burns about $24.4M/quarter from operations, an estimated runway of 15.1 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 50 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when RNAC files for a raise →

👥 Who Owns RNAC

Insiders 53.9% Institutions (134 holders) 28.9% Public and other holders 17.2%
HolderTypeShares% of sharesAs of
Timothy A Springer
Director, 10% owner · +7,800 options
Insider 9,633,493 31.58% 2026-01-02
Murat Kalayoglu
10% owner · +41,462 options
Insider 5,820,260 19.08% 2026-04-02
Elizabeth Hoge
10% owner · +33,662 options
Includes shares also reported by Murat Kalayoglu, counted once
Insider 5,820,260 19.08% 2026-04-02
Squarepoint Ops LLC Institution (13G, 5%+) 2,209,601 7.24% 2026-03-09
Blackrock Inc. Institution (13F) 808,458 2.65% 2026-09-30
683 Capital Management LLC Institution (13F) 751,000 2.46% 2026-09-30
Vanguard Capital Management LLC Institution (13F) 555,823 1.82% 2026-09-30
FMR, LLC Institution (13F) 370,457 1.21% 2026-09-30
Two Sigma Investments, LP Institution (13F) 367,350 1.20% 2026-09-30
Geode Capital Management, LLC Institution (13F) 342,829 1.12% 2026-09-30
Carsten Brunn
President and CEO, Director · +783,833 options
Insider 323,530 1.06% 2026-01-06
AQR Capital Management, LLC Institution (13F) 287,156 0.94% 2026-09-30

Share count 30,503,005 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-04-02
filed 2026-04-06
Seven One Eight Three Four…
Option exercise (M) 758,001 – 5,313,261
2026-04-02
filed 2026-04-06
Seven One Eight Three Four…
Option exercise (M) 22,740 – –
2026-04-02
filed 2026-04-06
Kalayoglu Murat
Option exercise (M) 758,001 – 5,313,261
2026-04-02
filed 2026-04-06
Kalayoglu Murat
Option exercise (M) 22,740 – –
2026-03-13
filed 2026-03-13
Singer Michael
Gift (G) 6,555 – 49,578

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full RNAC picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RNAC and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.